SCHEMBL25319462

SCHEMBL25319462

Brc1ncc(Br)c2c1cnn2C1CCCCO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP4F2 P78329 5/20 0.38
▸ CYP4A11 Q02928 5/20 0.38
▸ RXRA P19793 1/20 0.35
▸ RXRB P28702 1/20 0.35
▸ RXRG P48443 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP2C19 P33261 1/20 0.34
▸ ATR Q13535 4/20 0.32
▸ PDE9A O76083 1/20 0.32
▸ KDM5B Q9UGL1 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ YTHDC1 Q96MU7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30551537 1.00 RET (0.41) RETALDH1A1POLBLMNACYP4F2
SCHEMBL25324455 0.87 RET (0.42) RETALDH1A1POLBLMNACYP4F2
SCHEMBL25323920 0.87 RET (0.48) RETALDH1A1POLBLMNACYP4F2
SCHEMBL25328103 0.83 RET (0.38) RETALDH1A1POLBLMNACYP4F2
SCHEMBL25322203 0.77 ALDH1A1 (0.45) RETALDH1A1POLBLMNACYP4F2
SCHEMBL20324247 0.76 CYP4F2 (0.44) RETALDH1A1POLBLMNACYP4F2
SCHEMBL29705330 0.76 CYP4F2 (0.41) RETALDH1A1POLBLMNACYP4F2
SCHEMBL29705447 0.76 ALDH1A1 (0.39) RETALDH1A1POLBLMNACYP4F2
SCHEMBL30860948 0.76 CYP4F2 (0.44) RETALDH1A1POLBLMNACYP4F2
SCHEMBL29705440 0.76 ALDH1A1 (0.45) RETALDH1A1POLBLMNACYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN RET 1025/4885ALDH1A1 79/4885POLB 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback